AM I NEXT? NO LOVE AT GOODRX

Santa Monica, California-based GoodRx, a platform for prescription price comparisons and discount programs, has announced a major personnel realignment affecting 16% of the company's workforce.

Approximately 140 employees will be impacted, primarily in the company's technology and marketing teams.

According to GoodRx's chief financial officer Karsten Voermann, "The company is focused on efficiently growing its core prescriptions business, accelerating its pharma manufacturer solutions business and doubling down on consumer engagement. As the company focuses on these goals, it is consolidating functions and eliminating or reducing investment in areas of lower focus."

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something bad hasn't happened yet, doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?

AM I NEXT? NO LOVE AT NEKTAR THERAPEUTICS (06/01/22)

JUNE 1, 2022 — 72 EMPLOYEE LAYOFFS IN HUNTSVILLE, ALABAMA

The company has announced 72 layoffs in Huntsville, Alabama with separations scheduled for June 26, 2022.

MAY 12, 2022 — Original post…

San Francisco, California-based Nektar Therapeutics, a biopharmaceutical using its proprietary process to develop drugs, has announced its plans to reduce operating expenses after the failure of its cancer drug partnership with Bristol Myers Squibb.

The cost-cutting initiative will impact 70% of the company's workforce or approximately 500 employees.

According to Nektar's CEO, Howard Robin, he was “shocked and devastated” by the latest drug trial in combination with a Bristol Myers Squibb drug. “This new strategic plan refocuses our entire company around specific and prudent investments into our most important pipeline programs, NKTR-358, NKTR-255 and preclinical candidates, each of which we believe presents an opportunity to create significant value for our shareholders."

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. Just because something bad hasn't happened yet, doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?

AM I NEXT? NO LOVE AT BLUEBIRD BIO

Cambridge, Massachusetts-based Bluebird Bio, a biotechnology company specializing in gene-based biologics and therapies, has announced a cost-cutting initiative following a review of its strategic priorities. The company is also considering other options to raise cash, including equity financings and selling any priority review vouchers it hopes to get with upcoming FDA approvals.

The restructuring will impact 30% of the Bluebird Bio workforce, approximately 360 employees.

According to company CEO Andrew Obenshain, "Today, we are taking decisive action to extend our cash runway and put bluebird in a stronger position to execute on our strategic priorities and ultimately bring potentially curative gene therapies to patients and their families. The decision to reduce our workforce in support of a more focused set of priorities was not taken lightly, and we are grateful to every bluebird who has helped to progress the field of gene therapy and championed our mission."

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. Just because something bad hasn't happened yet, doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?